HC Wainwright投资公司将PepGen的EPS2027财政年度估计数从0.8美元降至0.04美元。 Investment firm HC Wainwright reduces PepGen's FY2027 EPS estimate from $0.08 to $0.04.

HC Wainwright公司将PepGen的EPS2027财政年度估计值从0.08美元降至0.04美元。 Firm HC Wainwright reduces PepGen's FY2027 EPS estimate to $0.04 from $0.08. PepGen专注于开发用于严重神经肌肉和神经系统疾病的寡核苷酸疗法，主要候选产品PGN-EDO51处于杜氏肌营养不良症的2期试验中。 PepGen focuses on developing oligonucleotide therapeutics for severe neuromuscular & neurologic diseases, with lead product candidate PGN-EDO51 in Phase 2 trials for Duchenne muscular dystrophy. Vanguard Group在第一季度增持了68%的股份，而美国银行将其评级下调至“中性”，目标价为12美元。 Vanguard Group increased its stake in Q1 by 68%, while Bank of America downgraded to 'neutral' with a $12 target.